Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.53 CHF | +1.19% | -0.66% | +0.78% |
Apr. 19 | US FDA mandates label updates on CAR-T cancer therapies | RE |
Apr. 18 | NOVARTIS AG : UBS reiterates its Buy rating | ZD |
Sales 2024 * | 48.15B 43.8B | Sales 2025 * | 49.87B 45.36B | Capitalization | 206B 187B |
---|---|---|---|---|---|
Net income 2024 * | 10.62B 9.66B | Net income 2025 * | 11.58B 10.53B | EV / Sales 2024 * | 4.53 x |
Net Debt 2024 * | 11.85B 10.78B | Net Debt 2025 * | 10.14B 9.23B | EV / Sales 2025 * | 4.34 x |
P/E ratio 2024 * |
18.5
x | P/E ratio 2025 * |
16.4
x | Employees | 76,057 |
Yield 2024 * |
3.89% | Yield 2025 * |
4.02% | Free-Float | 81.95% |
Latest transcript on Novartis AG
1 day | +1.19% | ||
1 week | -0.66% | ||
Current month | -2.11% | ||
1 month | +0.01% | ||
3 months | -8.82% | ||
6 months | +0.92% | ||
Current year | +0.78% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 18 M€ | +1.40% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 85.53 | +1.19% | 3,719,061 |
24-04-18 | 84.52 | -0.39% | 2,681,710 |
24-04-17 | 84.85 | -0.18% | 2,429,911 |
24-04-16 | 85 | -1.73% | 3,068,722 |
24-04-15 | 86.5 | +0.46% | 2,331,975 |
Delayed Quote Swiss Exchange, April 19, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.78% | 203B | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
-9.69% | 144B | |
-6.63% | 141B | |
-3.20% | 113B |
- Stock Market
- Equities
- NOVN Stock